SUPN News and Press, Supernus Pharmaceuticals Inc. From 05/07/24

2024-05-07 17:20:52 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals: Moving Through An 'Inflection Year' Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript Supernus stock slides as FDA rejects Parkinson's disease infusion device ...

Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree ® The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022) 1 Although symptoms are present in childhoo...

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and busi...

2024-04-14 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-08 12:00:03 ET Irene Buhalo from Jefferies issued a price target of $40.00 for SUPN on 2024-04-08 10:10:00. The adjusted price target was set to $40.00. At the time of the announcement, SUPN was trading at $32.265. SUPN currently trades -16.55% versus its 52 week...

2024-04-08 08:39:34 ET Supernus Pharmaceuticals ( NASDAQ: SUPN ) shares dipped ~11% premarket on Monday after the U.S. drug regulator rejected its experimental apomorphine infusion device for the continuous treatment of motor fluctuations associated with Parkinson’s d...

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is ...

2024-04-05 01:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-15 22:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Super...